Greater Capacity. Additional Services. A World-class facility
At Sharp, we want to be able to offer you greater capacity in manufacturing and distributing your clinical trial materials. We also want to offer you a broader range of integrated services from a world-class clinical facility.
So, we are relocating our UK-based clinical services facility.
With the support of our parent company UDG Healthcare, Sharp last year purchased a packaging facility in Rhymney, South Wales. Since then it has been undergoing significant redevelopment to become a multi-phase pharmaceutical manufacturing, packaging and distribution facility.
We look forward to bringing you a broader service offering from this new, world-class clinical site from November 2018.
Sharp Clinical Services
Sharp Clinical Services, part of UDG Healthcare plc, has announced a £9 million investment to fund a new multiple-phase pharmaceutical manufacturing, packaging and distribution facility in Wales. Discussing the new development, Frank Lis, president of Sharp Clinical Services, said:
“We are currently working at capacity at our site in Crickhowell, so this investment gives us a blank canvas to design a modern contract packaging, manufacturing and distribution facility that meets the evolving needs of drug development companies with single or multiple products at any clinical scale. The move to the Rhymney site will enable us to offer expanded capacity, scalability and automation, meaning we can simultaneously support multiple large scale Phase III studies, as well as projects at an earlier trial stage. It will also allow us to grow both the Sharp team to support current business and to expand our clinical services portfolio to new customers, at a larger scale.”
Click here to read more about the investment, which also includes £500,000 from the Welsh Government, will enable the company to satisfy increased demand for Phase III clinical and commercial services.